Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248081 | 0.81 | FAAH (0.35) | FAAH | |
| SCHEMBL3741553 | 0.81 | FAAH (0.35) | FAAH | |
| SCHEMBL7392842 | 0.79 | AAK1 (0.45) | FAAH | |
| SCHEMBL6671292 | 0.79 | AAK1 (0.45) | FAAH | |
| SCHEMBL7392844 | 0.79 | AAK1 (0.45) | FAAH | |
| SCHEMBL8647816 | 0.77 | FAAH (0.33) | FAAH | |
| SCHEMBL18125957 | 0.77 | RNPEP (0.43) | RNPEPSLC7A5CPA1 | |
| SCHEMBL6675474 | 0.76 | CA2 (0.36) | FAAH | |
| SCHEMBL6675478 | 0.76 | CA2 (0.36) | FAAH | |
| SCHEMBL6674233 | 0.76 | FAAH (0.32) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | FAAH 2901/4885RNPEP 1306/4885SLC7A5 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.